

PRESS RELEASE

ANTARES VISION GROUP: AGREEMENTS SIGNED FOR “NEXT GEN EU” RESEARCH PROJECTS WORTH APPROX. €900 MILLION

The Group is the technological partner in the Life Science, Agritech and Digital Healthcare sectors, in collaboration with the Italian Institute of Technology, leading Hospitals, Italian Universities and a network of private companies

Travagliato (Brescia), 19 July 2022 - Antares Vision Group, (EXM, AV:IM) Italian multinational, leading provider in Track & Trace systems and quality control, which guarantee the transparency of products and supply chains through integrated data management, is the technological partner in three research and innovation projects funded by the European Union, through the NextGenerationEU programme, worth a total of approximately €900 million.

The projects are part of the most recent programme sponsored by the Italian Ministry of University and Research, the strategic objective of which is to create “national champions” of research and development in certain “Key Enabling Technologies”, as part of the “National Recovery and Resilience Plan - NRRP”, funded by the European Union within the NextGenerationEU programme.

*“To accomplish these projects - **commented Emidio Zorzella, Chairman and Joint-CEO of Antares Vision Group** - the Group provides its know-how, expertise and ecosystem of its technology solutions: from traceability, inspection for quality control, to integrated data management also with the application of artificial intelligence. The aim is to provide a technology platform to ensure the safety, transparency, efficiency and sustainability of products, processes and supply chains. The added value of these partnerships - Zorzella concludes - is the ability to create a system between businesses and outstanding Entities through technology, aimed at ensuring innovation for people’s health and safety and thus a better quality of life”.*

In the **Life Science** sector, the Group has signed an agreement, as founder, for the “Development of gene therapy and drugs with RNA technology” with the National Research Centre based in Padua, with funding of €400 million. The Centre, established in collaboration with the University of Brescia, has the two-fold objective of increasing the technological know-how needed to design and provide RNA-based medicines, and for gene therapy, and to identify promising candidate drugs and genes in five main disease areas: genetic diseases, cancer, metabolic-cardiovascular diseases, neurodegenerative diseases and inflammatory-infectious diseases. Once up and running, the Research Centre is envisaged to reach a production capacity of up to 250-300 drugs per year dedicated to gene therapy.

In the **AgriTech** sector, Antares Vision Group has signed an agreement with the National Research Centre for “Agricultural - Agritech Technologies” at the University of Naples Federico II, with funding of €477 million. The aim of the Centre is to work to increase sustainable productivity, to meet food safety requirements and to reduce the environmental impact in variable climatic conditions, through five research objectives: resilience (to improve sustainable productivity and to promote resilience to climate change), low impact (to reduce waste and environmental impact), circularity (to develop circular economy strategies), recovery (the sustainable development of marginal areas), traceability (to promote safety, traceability and authenticity in agrifood supply chains).

PRESS RELEASE

Lastly, in the **Digital Healthcare** segment, the Italian multinational has signed an agreement with the University of Brescia and Dompè Farmaceutici to develop an integrated system of healthcare infrastructure, which will extend the Multi-sector Technological Service Centre of the Nord University Campus by around 2,000 square metres, with a view to developing healthcare technologies of the future. The project stems from a public and private sector partnership called LIGHT (Lifescience Innovation Good Healthcare Technology), which has collected over €19.5 million in funds.

ABOUT ANTARES VISION GROUP

Antares Vision Group is an outstanding technology partner in digitalization and innovation for companies and institutions, guaranteeing the safety of products and people, business competitiveness as well as environmental protection. The Company provides a unique and comprehensive ecosystem of technologies to guarantee product quality (inspection systems and equipment) and end-to-end product traceability (from raw materials to production, from distribution to the consumer) through integrated data management, applying artificial intelligence and blockchain technology. The Antares Vision Group is active in Life Science (pharmaceutical, biomedical devices and hospitals) and in FMCG (Fast-Moving Consumer Goods). As a world leader in Track & Trace solutions for pharmaceutical products, the Company provides major global manufacturers (over 50% of the top 20 multinationals) and numerous government authorities with solutions, monitoring their supply chains and validating product authenticity. Listed since April 2019 on the Italian Stock Exchange in the AIM (Alternative Investment Market) segment, and from 14 May 2021 in the STAR segment of Euronext, Antares Vision Group recorded a turnover of €179 million in 2021, operates in 60 countries, employs more than 1000 people and has a consolidated network of over 40 international Partners. Further information please visit www.antaresvision.com and www.antaresvisiongroup.com.

For further information

Antares Vision Group

Alessandro Baj Badino

Head of Investor Relations

Tel.: +39 030 72 83 500

E-mail: investors@antaresvision.com

Davide Antonioli

Investor Relator

+39 030 7283500

E-mail: investors@antaresvision.com

Press contacts

Axelcomm

Federica Menichino

Cell. +39 3496976982

E-mail: federica.menichino@axel-comm.it